Sasan Amini, Founder & CEO

Clear Labs

Pioneering Descriptive Diagnostics
Simultaneous detection and surveillance/further characterization of pathogens



Legacy Diagnostics
1 Bit of Information
PCR/Immunoassays
Which pathogen



Descriptive Diagnostics
10^8 Bits of Information
Next Generation Sequencing (NGS)
Which pathogen + which antibiotics it responds to?

Clear Labs Confidential

Clear Labs

The only fully automated Next Generation Sequencing (NGS) platform for descriptive diagnostic

1. Ease of use (walk-away automation)
2. Integrated solution (end-to-end)
3. Seamless integration of data analytic pipelines
4. Faster time to result
5. Cost-effective
6. Superior performance (sensitivity, specificity)
7. Pathogen-agnostic option
8. Reproducibility
9. Alternative supply chain
10. Reliability

Clear Labs

Growing number of public health labs select Clear Dx as the platform of choice



On-track to be Deployed in 50%+ of PHLs in US by the End of Q3
Starting from first week of January

PHL Success Stories Using Clear Dx

#1 State in percentage of positive COVID samples sequenced

All the fastest states in terms of data sharing with GISAID are all Clear Dx users

#1 case of alpha and delta variants identified in several states in near-real time

Clear Labs

Staying one step ahead of the pathogen

Near real-time pathogen monitoring engine

Actual Events

Case of B.1.1.7 in United Kingdom

Accelerated Scenario

Retrospective Study of B.1.1.7 w/ Clear Labs New Variant Monitoring System